imatinib mesylate has been researched along with Flushing in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barete, S; Casassus, P; Eclache, V; Fain, O; Hermine, O; Lorholary, O; Stirnemann, J | 1 |
| Bouché, O; Cadiot, G; Delattre, JF; Diébold, MD; Guillou, PJ; Lagarde, S; Lubrano, D; Nguyen, TD; Ramaholimihaso, F; Thiéfin, G | 1 |
1 review(s) available for imatinib mesylate and Flushing
| Article | Year |
|---|---|
[Systemic mastocytosis].
Topics: Benzamides; Biomarkers; Bone and Bones; Cell Differentiation; Cell Division; Cladribine; Diphosphonates; Flushing; Histamine H1 Antagonists; Histamine Release; Imatinib Mesylate; Interferon-alpha; Leukotriene Antagonists; Mast Cells; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Serine Endopeptidases; Stem Cell Factor; Tachycardia; Tryptases | 2005 |
1 other study(ies) available for imatinib mesylate and Flushing
| Article | Year |
|---|---|
[Flushing revealing the recurrence of a rectal gastrointestinal stromal tumour. Efficacy of imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Flushing; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Rectal Neoplasms | 2006 |